- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT07909590
A Study Evaluating the Impact of a Painkiller Product on Quality-of-Life and Daily Functioning
A Multi-country, Retrospective, Real World Observational Study Evaluating the Impact of an Analgesic Product on Quality-of-Life and Daily Functioning
The aim of this study is to generate real-world, consumer reported evidence on the perceived impact of headache relief with Panadol/Dolex on Quality of Life (QoL) and daily functioning.
Study Overview
Detailed Description
This is a multi-country, real-world, observational, cross-sectional survey study. The target population for this survey study comprises individuals who have used Panadol/Dolex for the relief of more than or equal to (>=)1 headache episode in the past 1 month. Eligible participants will be directed to complete an online survey comprising of a series of questions designed to gather data relevant to the research objectives. The study population will be comprised of approximately 2,100 participants across Australia, Malaysia, Colombia, and Kenya.
Study Type
Enrollment (Estimated)
Contacts and Locations
Study Contact
- Name: Haleon Response Center
- Phone Number: +441932 95 95 00
- Email: ww.clinical-trial-register@haleon.com
Study Locations
-
-
Marina Centre
-
Singapore, Marina Centre, Singapore
- Virtual site
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Residents of Australia, Malaysia, Colombia, Kenya who have experienced acute primary headaches that occur 1 to 14 days a month on average in the past 1 month and have taken Panadol/Dolex for at least 1 headache episode in the past 1 month.
Description
Inclusion Criteria:
- Residents of Australia, Malaysia, Colombia, Kenya.
- Have experienced acute primary headaches that occur 1 to 14 days a month on average in the past 1 month.
- Have taken Panadol/Dolex for at least 1 headache episode in the past 1 month.
- Self-reported healthy individuals.
- Able to provide informed consent.
- The specific Panadol/Dolex variant for each country as applicable.
Exclusion Criteria:
- Participants who experience headaches that occur 15 or more days per month.
- Participants with migraine.
- Participants who use any headache medication, pain relief product or alternative remedy (herbal products, supplements, CBD [cannabidiol]- containing pain remedies) concurrently with Panadol/Dolex for the recalled headache episode in the past 1 month.
- Participants diagnosed by a healthcare professional with chronic pain conditions (fibromyalgia, neuropathic pain, cancer, lupus, multiple sclerosis) who were experiencing symptoms or receiving treatment for the condition at the time of reference headache episode when Panadol/Dolex was used.
- Breastfeeding or Pregnant at the time of reference headache episode during which Panadol/Dolex was used.
- Participants affiliated with Sponsor or Contract Research Organization (CRO).
Study Plan
How is the study designed?
Design Details
- Observational Models: COHORT
- Time Perspectives: CROSS_SECTIONAL
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
|---|---|
|
Panadol/Dolex Tablet
Participants who have taken Panadol/Dolex for at least 1 headache episode in the past 1 month. |
Paracetamol 500 milligram (mg) taken orally. |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Pain Intensity Before Using Panadol/Dolex
Time Frame: Within the past 1 month from time of participation
|
Thinking about most recent headache episode, participants will be asked to rate the pain intensity experienced before using Panadol/Dolex on a scale 0 to 10, where 0= No pain and 10= Worst possible pain. Lower score indicates better outcome. |
Within the past 1 month from time of participation
|
|
Perceived Relief From Panadol/Dolex Use
Time Frame: Within the past 1 month from time of participation
|
Thinking about the headache episode, participants will describe the first sign of symptom relief they perceived after taking Panadol/Dolex. |
Within the past 1 month from time of participation
|
|
QoL Assessment After Using Panadol/Dolex Post Headache Episode
Time Frame: Within the past 1 month from time of participation
|
Thinking about most recent headache episode, participants will be asked to respond to 10 questions related to aspects of daily life when they used Panadol/Dolex after headache episode. The response will be scored using a 5-point scale, where 1= Not at all, and 5= Very Much. Lower score indicates better quality of life. |
Within the past 1 month from time of participation
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Frequency of Panadol/Dolex Use
Time Frame: Within the past 1 month from time of participation
|
Thinking about the recent headache episode, participants will be asked to mention the frequency of product use from 1 time a day to 4 times a day. |
Within the past 1 month from time of participation
|
|
Timepoint of Panadol/Dolex Use
Time Frame: Within the past 1 month from time of participation
|
Participants will answer a single question related to timepoint of product use- 'Thinking about the same headache episode which you used Panadol for relief in the past one month, what did you first do to relieve the pain?' Participants will choose one of the given options. |
Within the past 1 month from time of participation
|
|
Product Satisfaction
Time Frame: Within the past 1 month from time of participation
|
Thinking about the experience of using Panadol, participants will rate their overall satisfaction on a scale 1 to 5, where 1= Absolutely dissatisfied and 5= Completely satisfied. |
Within the past 1 month from time of participation
|
|
Headache Management Behaviors
Time Frame: Within the past 1 month from time of participation
|
Participants will answer a single question related to headache management approaches they used before- 'Thinking about similar headaches you experienced before this episode, what did you do to relieve your headache in the past?' Participants will select one or more descriptive options provided. |
Within the past 1 month from time of participation
|
|
User Attitudes Towards Panadol/Dolex: Trust in The Product
Time Frame: Within the past 1 month from time of participation
|
Participants will answer a single question related to trust in the product- 'How much do you trust the product to provide fast headache pain relief?' Participants will choose one of the given options. |
Within the past 1 month from time of participation
|
|
User Attitudes Towards Panadol/Dolex: Value For Money
Time Frame: Within the past 1 month from time of participation
|
Thinking about experience of using the product, participants will be asked to rate the product's value for money on a scale 1 to 5, where 1= Poor value for money and 5= Excellent value for money. |
Within the past 1 month from time of participation
|
|
User Attitudes Towards Panadol/Dolex: Intention to Use Again
Time Frame: Within the past 1 month from time of participation
|
Participants will answer a single question related to continued purchase- 'How likely would you choose Panadol again for your next headache episode?'. Participants will choose one of the given options. |
Within the past 1 month from time of participation
|
|
User Attitudes Towards Panadol/Dolex: Intention to Recommend Other Consumers
Time Frame: Within the past 1 month from time of participation
|
Participants will answer a single question related to likelihood to recommend others- How likely would you recommend Panadol to other consumers experiencing headache pain? Participants will choose one of the given options. |
Within the past 1 month from time of participation
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Estimated)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 400384
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Anonymized individual participant data and study documents can be requested for further research from ww.clinical-trial-register@haleon.com
IPD Sharing Time Frame
IPD will be made available within 6 months of publishing the results of the primary endpoints, key secondary endpoints and safety data of the study.
IPD Sharing Access Criteria
Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months, but an extension can be granted, when justified, for up to another 12 months.
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- SAP
- ICF
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.